Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

Accept all cookies Reject all non-essential cookies Find out more

6. References

  1. Aung T, Haynes R, Barton J, et al. Cost-effective recruitment methods for a large randomised trial in people with diabetes: A Study of Cardiovascular Events iN Diabetes (ASCEND). Trials 2016;17:286.
  2. Bowman L, Mafham M, Stevens W, et al. ASCEND: A Study of Cardiovascular Events iN Diabetes: Characteristics of a randomized trial of aspirin and of omega-3 fatty acid supplementation in 15,480 people with diabetes. American Heart Journal 2018;198:135-44.
  3. Dunlay SM, Givertz MM, Aguilar D, et al. Type 2 Diabetes Mellitus and Heart Failure: A Scientific Statement From the American Heart Association and the Heart Failure Society of America: This statement does not represent an update of the 2017 ACC/AHA/HFSA heart failure guideline update. Circulation 2019;140:e294-e324.
  4. Arenja N, Mueller C, Ehl NF, et al. Prevalence, Extent, and Independent Predictors of Silent Myocardial Infarction. The American Journal of Medicine 2013;126:515-22.
  5. Kannel WB, McGee DL. Diabetes and Cardiovascular Disease: The Framingham Study. Journal of the American Medical Association 1979;241:2035-8.
  6. Qureshi WT, Zhang Z-M, Chang PP, et al. Silent Myocardial Infarction and Long-Term Risk of Heart Failure: The ARIC Study. Journal of the American College of Cardiology 2018;71:1-8.
  7. The ASCEND Study Collaborative Group. Effects of n−3 Fatty Acid Supplements in Diabetes Mellitus. New England Journal of Medicine 2018;379:1540-50.
  8. Bhatt DL, Steg PG, Miller M, et al. Cardiovascular Risk Reduction with Icosapent Ethyl for Hypertriglyceridemia. New England Journal of Medicine 2018;380:11-22.
  9. Djoussé L, Cook NR, Kim E, et al. Supplementation With Vitamin D and Omega-3 Fatty Acids and Incidence of Heart Failure Hospitalization. Circulation 2020;141:784-6.
  10. Djoussé L, Cook NR, Kim E, et al. Diabetes Mellitus, Race, and Effects of Omega-3 Fatty Acids on Incidence of Heart Failure Hospitalization. JACC Heart Failure 2022;10:227- 34.
  11. Valensi P, Meune C. Congestive heart failure caused by silent ischemia and silent myocardial infarction. Herz 2019;44:210-7.
  12. Zannad F, Pfeffer MA, Bhatt DL, et al. Streamlining cardiovascular clinical trials to improve efficiency and generalisability. Heart 2017;103:1156-62.
  13. Calvo G, McMurray JJV, Granger CB, et al. Large streamlined trials in cardiovascular disease. European Heart Journal 2014;35:544-8.
  14. Van Staa T-P, Goldacre B, Gulliford M, et al. Pragmatic randomised trials using routine electronic health records: putting them to the test. British Medical Journal 2012;344:e55.
  15. Huang H, Turner M, Raju S, et al. Identification of Acute Decompensated Heart Failure Hospitalizations Using Administrative Data. American Journal of Cardiology 2017;119:1791- 6.
  16. McCormick N, Lacaille D, Bhole V, Avina-Zubieta JA. Validity of heart failure diagnoses in administrative databases: A systematic review and meta-analysis. PLoS ONE 2014;9.
  17. Yusuf S, Peto R, Lewis J, Collins R, Sleight P. Beta blockade during and after myocardial infarction: an overview of the randomized trials. Progress in Cardiovascular Disease 1985;27:335-71.
  18. Peto R, Pike MC, Armitage P, et al. Design and analysis of randomized clinical trials requiring prolonged observation of each patient. II. analysis and examples. British Journal of Cancer 1977;35:1-39.
  19. Landis JR, Koch GG. The measurement of observer agreement for categorical data. Biometrics 1977;33:159-74. 20. Fleiss JL, Levin B, Paik MC. Statistical Methods for Rates and Proportions (3rd ed.). John Wiley & Sons; 2013.

2022-07-21 HF-ASCEND Main Data Analysis Plan V1.0 [PDF]